Log In
BCIQ
Print this Print this
 

Autologous T cell therapy against CD19 (KTE-C19)

  Manage Alerts
Collapse Summary General Information
Company Kite Pharma Inc.
DescriptionAutologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19
Molecular Target CD19
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/17/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today